keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
Published 4 years ago • 246 plays • Length 8:05Download video MP4
Download video MP3
Similar videos
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
4:24
comment: pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
6:52
immunotherapy added to chemotherapy improves pathological complete response in early triple nega...
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
3:34
neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in os
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
3:49
keynote-522: neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs place...
-
1:29
immunotherapy keytruda shows benefit in early triple-negative breast cancer
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
4:22
immunotherapy in early triple-negative breast cancer: new data and future directions
-
2:21
the challenges of treating early-stage tnbc
-
7:36
esmo 2020 expert video report on atezolizumab in upfront treatment of tnbc